Adoptive Cellular Immunotherapy Using Cd1a CART-Cells for Cortical T-Cell Acute Lymphoblastic Leukemia

Pablo Menéndez; Diego Sánchez‐Martínez

doi:10.1016/j.exphem.2018.06.089

ScienceGate Book Chapters

JOURNAL ARTICLE

Adoptive Cellular Immunotherapy Using Cd1a CART-Cells for Cortical T-Cell Acute Lymphoblastic Leukemia

Pablo Menéndez Diego Sánchez‐Martínez

Year: 2018 Journal: Experimental Hematology Vol: 64 Pages: S84-S85 Publisher: Elsevier BV

DOI: 10.1016/j.exphem.2018.06.089

Get Full-Text PDF Get Analytical Report

Keywords:

Immunotherapy Chimeric antigen receptor CD8 Adoptive cell transfer CD19 Immunology Cell therapy T cell Cytotoxic T cell Antigen Cancer research Medicine Biology In vitro Immune system Stem cell Cell biology

Metrics

Cited By

0.00

FWCI (Field Weighted Citation Impact)

Refs

0.12

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

CAR-T cell therapy research

Health Sciences → Medicine → Oncology

Acute Lymphoblastic Leukemia research

Health Sciences → Medicine → Public Health, Environmental and Occupational Health

CRISPR and Genetic Engineering

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Adoptive Cellular Immunotherapy Using Cd1a CART-Cells for Cortical T-Cell Acute Lymphoblastic Leukemia

Metrics

Topics

Related Documents

Adoptive Cellular Immunotherapy using CD1a CART-cells for Treatment of Cortical Pediatric T-Cell Acute Lymphoblastic Leukemia

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

Immunotherapy of pediatric acute lymphoblastic B-cell leukemia using gene-modified T cells

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells